BI 3820768 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=187 | Recruiting | Sponsor: Boehringer Ingelheim | Trial primary completion date: Apr 2029 ➔ Sep 2029

Trial primary completion date • Endometrial Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Boehringer Ingelheim | N=65 ➔ 102

Enrollment change • Trial initiation date • Endometrial Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

2001-0001: A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours) (clinicaltrialsregister.eu) - P1 | N=65 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

New P1 trial • Endometrial Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=187 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2029 ➔ Dec 2029

Enrollment open • Trial completion date • Endometrial Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=187 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Endometrial Cancer • Germ Cell Tumors • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor